Abstract
Adverse drug events (ADEs) are a critical aspect of patient safety and pharmacovigilance, with significant implications for patient outcomes and public health monitoring. The increasing availability of electronic health records, social media, and online patient forums provides valuable yet challenging unstructured data sources for ADE surveillance. To address these challenges, we introduce CONORM, a novel framework that integrates named entity recognition (NER) and entity normalization (EN) for ADE extraction across diverse textual domains. CONORM comprises two components: CONORM-NER, a subword-aware, transformer-based model for ADE detection, and CONORM-EN, an entity normalization module using dual-encoder embeddings and dynamic context refining. CONORM was evaluated on SMM4H 2023 (tweets), CADEC (forum posts), and TAC (product labels), where it consistently outperformed existing methods. It achieved end-to-end F1-scores of 63.86% on SMM4H, 72.45% on CADEC, and 84.99% on TAC, surpassing existing solutions by an average margin of 35%. The results demonstrate CONORM’s adaptability across informal, semi-formal, and formal text sources. Stratified analyses showed stronger results for well-represented system organ classes (SOCs) and moderate-to-long contexts. CONORM offers a scalable and reproducible solution for real-world pharmacovigilance, with pre-computed target embeddings enhancing inference efficiency for large medical ontologies. Its generalization capabilities across diverse text domains establish it as a robust tool for ADE surveillance. To support reproducibility, all source code is publicly available at https://github.com/ds4dh/CONORM. Future work will explore multilingual capabilities, rare SOC data augmentation, and optimizations for long-form narratives.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Innosuisse - project no.: 55441.1 IP ICT.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.